GlassScriptPhysician profile
Eunice Lee
NPI 1093272338
$3,046.48
in general payments reported to CMS, 2019-2025
12 companies · $21.96 in 2025
The $21.96 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,264 · 2022: $778 · 2023: $715 · 2024: $268 · 2025: $21.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $960.27 | 2021-2023 | Spravato |
| Alkermes, INC. | $487.02 | 2021-2023 | Aristada, Lybalvi, Aristada Initio |
| Indivior INC. | $349.72 | 2021-2023 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $337.48 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $220.33 | 2021-2023 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $178.33 | 2021 | |
| Glaxosmithkline, LLC. | $125.83 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Neurocrine Biosciences, INC. | $115.98 | 2023 | Ingrezza |
| Abbvie INC. | $108.74 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $96.19 | 2024 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $50.95 | 2024 | Uzedy |
| Boston Scientific Corporation | $15.64 | 2023 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eunice Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.